Immune-checkpoint blockade in cisplatin-ineligible patients with urothelial cancer

Lancet. 2017 Jan 7;389(10064):6-7. doi: 10.1016/S0140-6736(16)32516-8. Epub 2016 Dec 8.

Authors

Bishoy M Faltas¹, Scott T Tagawa²

Affiliations

¹ Division of Hematology and Medical Oncology, Meyer Cancer Center, Weill-Cornell Medicine, New York, NY 10065, USA.
² Division of Hematology and Medical Oncology, Meyer Cancer Center, Weill-Cornell Medicine, New York, NY 10065, USA. Electronic address: [email protected].

PMID: 27939401
DOI: 10.1016/S0140-6736(16)32516-8

No abstract available

Publication types

Comment

MeSH terms

Cisplatin*
Humans
Urinary Bladder Neoplasms*

Substances

Cisplatin